Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
J Urol
    June 2024
  1. DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
    Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
    J Urol. 2024;211:743-753.
    >> Share

    May 2024
  2. NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
    Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
    J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
    >> Share

  3. KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
    J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
    >> Share

    April 2024
  4. HOLZBEIERLEIN J, Bixler BR, Buckley DI, Chang SS, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (2017; Amended 2020, 2024).
    J Urol. 2024 Apr 25:101097JU0000000000003981. doi: 10.1097/JU.0000000000003981.
    >> Share

  5. KAY H, Silver SN, Smith AB, Basak R, et al
    Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
    J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
    >> Share

  6. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    >> Share

    March 2024
  7. MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
    Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
    J Urol. 2024;211:482-483.
    >> Share

  8. GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
    Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
    J Urol. 2024;211:476-480.
    >> Share

  9. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    >> Share

    February 2024
  10. WEISS K, Abimbola O, Mueller D, Basak R, et al
    Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
    J Urol. 2024;211:266-275.
    >> Share

  11. KAY H, Matulewicz RS, Bjurlin MA
    Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
    J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
    >> Share

    January 2024
  12. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    >> Share

    November 2023
  13. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    >> Share

    September 2023
  14. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    >> Share

  15. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    >> Share

  16. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    >> Share

  17. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    >> Share

  18. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    >> Share

  19. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    >> Share

    August 2023
  20. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    >> Share

  21. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    >> Share

    July 2023
  22. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    >> Share


  23. PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    >> Share

    June 2023
  24. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    >> Share

  25. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    >> Share

    May 2023
  26. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    >> Share

  27. TYSON MD, Morris D, Palou J, Rodriguez O, et al
    Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
    J Urol. 2023;209:890-900.
    >> Share

  28. GILBERT SM
    Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
    J Urol. 2023;209:833-835.
    >> Share

  29. GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
    A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
    J Urol. 2023;209:854-862.
    >> Share

  30. KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
    Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
    J Urol. 2023;209:882-889.
    >> Share

  31. YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
    Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:863-871.
    >> Share

  32. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
    J Urol. 2023;209:901-910.
    >> Share

  33. LABBATE C, Woldu S, Murray K, Rose K, et al
    Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:872-881.
    >> Share

    April 2023
  34. MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
    >> Share

  35. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    >> Share

  36. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    >> Share

    March 2023
  37. STEINBERG RL, O'Donnell MA, Packiam VT
    Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
    J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
    >> Share

  38. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    >> Share

  39. PRUNTY M, Shoag J
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy. Reply.
    J Urol. 2023;209:508-509.
    >> Share

  40. VANDEN BERG RNW, Abern M
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy. Letter.
    J Urol. 2023;209:508.
    >> Share

  41. MASTROIANNI R, Ochoa Arvizo MA, Torregiani G, Simone G, et al
    Robot-assisted vs Open Radical Cystectomy: Randomized Controlled Trials Lights and Shadows.
    J Urol. 2023;209:460-461.
    >> Share

  42. TISSOT G, Xylinas E
    Lymph Node Dissection in Upper Tract Urothelial Cancer: Ready for Prime Time?
    J Urol. 2023;209:462-463.
    >> Share

  43. PALLAUF M, D'Andrea D, Konig F, Laukhtina E, et al
    Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study.
    J Urol. 2023;209:515-524.
    >> Share

  44. MYERS A, Frank I, Shah PH, Tarrell RF, et al
    Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy.
    J Urol. 2023;209:525-531.
    >> Share

    February 2023
  45. CASTANEDA PR, Ahdoot M, Rosser CJ
    Re: Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomyis Prognostic but Not Therapeutic.
    J Urol. 2023 Feb 8:101097JU0000000000003362. doi: 10.1097/JU.0000000000003362.
    >> Share

  46. PRUNTY M, Rhodes S, Rivero MJ, Callegari M, et al
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy.
    J Urol. 2023;209:329-336.
    >> Share

  47. HUELSTER HL, Zemp L, Turner K, Gonzalez BD, et al
    Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility.
    J Urol. 2023;209:410-421.
    >> Share

    January 2023
  48. LYON TD, Boorjian SA, Tyson MD
    In-Home Intravesical Therapy: The Future of Non-muscle Invasive Bladder Cancer Care Delivery?. Letter.
    J Urol. 2023 Jan 13:101097JU0000000000003176. doi: 10.1097/JU.0000000000003176.
    >> Share

    October 2022
  49. LEE HW, Lee HH, Park EY, Park WS, et al
    Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately before Transurethral Resection of Bladder Tumor in Patients with Non-muscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2022 Oct 12:101097JU0000000000003002. doi: 10.1097/JU.0000000000003002.
    >> Share

  50. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic.
    J Urol. 2022 Oct 11:101097JU0000000000003015. doi: 10.1097/JU.0000000000003015.
    >> Share

  51. MATULEWICZ RS, Whiting K, Bochner BH, Ostroff JS, et al
    Knowledge of bladder cancer risk factors among patients diagnosed with non-muscle invasive bladder cancer.
    J Urol. 2022 Oct 4:101097JU0000000000002978. doi: 10.1097/JU.0000000000002978.
    >> Share

  52. NOGUEIRA LM, Yip W, Assel MJ, Tracey AT, et al
    Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma.
    J Urol. 2022;208:813-820.
    >> Share

    September 2022
  53. NAZMIFAR M, Williams C, Naser-Tavakolian A, Heard J, et al
    Clinical and Preclinical Therapies for Bladder Cancer Following BCG Failure.
    J Urol. 2022 Sep 6:101097JU0000000000002957. doi: 10.1097/JU.0000000000002957.
    >> Share

  54. PARISSE T, Reines K, Basak R, Mueller D, et al
    Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs. Chemoablation for Non-Muscle Invasive Bladder Cancer Treatment.
    J Urol. 2022 Sep 6:101097JU0000000000002941. doi: 10.1097/JU.0000000000002941.
    >> Share

  55. MEEKS JJ, Sexton WJ, Clark PE
    Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guerin.
    J Urol. 2022;208:526-527.
    >> Share

  56. TERRITO A, Gallioli A, Diana P, Boissier R, et al
    DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    J Urol. 2022;208:570-579.
    >> Share

    August 2022
  57. BREE KK, Hensley PJ, Lobo N, Brooks NA, et al
    All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors.
    J Urol. 2022;208:284-291.
    >> Share

  58. HAKIMI K, Carbonara U, Djaladat H, Mehrazin R, et al
    Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.
    J Urol. 2022;208:268-276.
    >> Share

    July 2022
  59. MCELREE IM, Steinberg RL, Martin AC, Richards J, et al
    Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2022 Jul 27:101097JU0000000000002740. doi: 10.1097/JU.0000000000002740.
    >> Share

  60. MCELREE IM, Packiam VT, Steinberg RL, Mott SL, et al
    Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder Cancer.
    J Urol. 2022 Jul 5:101097JU0000000000002848. doi: 10.1097/JU.0000000000002848.
    >> Share

  61. SONG Y, Du Y, Qin C, Bai F, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Letter.
    J Urol. 2022;208:222-223.
    >> Share

    June 2022
  62. GESSNER KH, Siemens DR, Bjurlin MA
    Re: Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Jun 21:101097JU0000000000002832. doi: 10.1097/JU.0000000000002832.
    >> Share

  63. ROSEN GH, Nallani A, Muzzey C, Murray KS, et al
    Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    J Urol. 2022;207:1302-1311.
    >> Share

    May 2022
  64. STOVER AM, Basak R, Mueller D, Lipman R, et al
    Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2022 May 31:101097JU0000000000002747. doi: 10.1097/JU.0000000000002747.
    >> Share

  65. KATES M, Mansour AM, Lamm DL, Shore N, et al
    Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer.
    J Urol. 2022 May 16:101097JU0000000000002778. doi: 10.1097/JU.0000000000002778.
    >> Share

  66. HUELSTER HL, Sexton WJ
    Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification.
    J Urol. 2022 May 2:101097JU0000000000002731. doi: 10.1097/JU.0000000000002731.
    >> Share


  67. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2022;207:1166.
    >> Share

  68. MASTROIANNI R, Ferriero M, Tuderti G, Anceschi U, et al
    Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
    J Urol. 2022;207:982-992.
    >> Share

    April 2022
  69. SONG Y, Du Y, Qin C, Xu T, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Letter.
    J Urol. 2022;207:937.
    >> Share

  70. YANAGISAWA T, Mori K, Motlagh RS, Kawada T, et al
    En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.
    J Urol. 2022;207:754-768.
    >> Share

  71. MATIN SF, Pierorazio PM, Kleinmann N, Gore JL, et al
    Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    J Urol. 2022;207:779-788.
    >> Share

  72. RICHTER LA, Osazuwa-Peters OL, Routh JC, Handa VL, et al
    Vaginal Complications after Cystectomy: Results from a Medicare Sample.
    J Urol. 2022;207:789-796.
    >> Share

    March 2022
  73. GESSNER KH, Siemens DR, Bjurlin MA
    Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Mar 15:101097JU0000000000002649. doi: 10.1097/JU.0000000000002649.
    >> Share

    February 2022
  74. MITRA AP, Cai J, Miranda G, Bhanvadia S, et al
    Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
    J Urol. 2022;207:302-313.
    >> Share

  75. MIEST T, Khanna A, Sharma V, Hensley PJ, et al
    Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy.
    J Urol. 2022;207:284-292.
    >> Share

    January 2022
  76. FURBERG H, Petruzella S, Whiting K, Stein E, et al
    Association of Biochemically Verified Post-diagnosis Smoking and Non-muscle Invasive Bladder Cancer Recurrence Risk.
    J Urol. 2022 Jan 27:101097JU0000000000002449. doi: 10.1097/JU.0000000000002449.
    >> Share

  77. MONAGHAN TF, Wagg AS, Rahman SN, Winer AG, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Letter.
    J Urol. 2022;207:237-238.
    >> Share

  78. CHESNUT GT, Goh AC
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Reply.
    J Urol. 2022;207:238-239.
    >> Share

  79. GOLD SA, Kenigsberg AP, Lotan Y
    Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
    J Urol. 2022;207:52-60.
    >> Share

    December 2021
  80. RIVEROS C, Jazayeri SB, Chalfant V, Ahmed F, et al
    The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
    J Urol. 2021 Dec 2:101097JU0000000000002342. doi: 10.1097/JU.0000000000002342.
    >> Share

  81. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply.
    J Urol. 2021;206:1531-1532.
    >> Share

  82. ALSYOUF M, Djaladat H
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy. Letter.
    J Urol. 2021;206:1530-1531.
    >> Share

  83. RAMAN JD, Kavalieris L, Konety B, Porten S, et al
    The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    J Urol. 2021;206:1380-1389.
    >> Share

  84. YANKELEVICH GR, Dreher PC, Taylor Z, Kim D, et al
    Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis.
    J Urol. 2021;206:1390-1402.
    >> Share

    November 2021
  85. MICHAEL J, Matulewicz RS, Bjurlin MA
    Assessment of Tobacco Screening and Smoking Cessation Recommendations Among Bladder Cancer Guidelines: A Call to Action.
    J Urol. 2021 Nov 30:101097JU0000000000002360. doi: 10.1097/JU.0000000000002360.
    >> Share

  86. OEFELEIN MG
    The Continued Importance of Transurethral Resection of Bladder Tumor (TURBT) in the Treatment of Bladder Cancer.
    J Urol. 2021 Nov 5:101097JU0000000000002325. doi: 10.1097/JU.0000000000002325.
    >> Share

  87. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy.
    J Urol. 2021;206:1132-1138.
    >> Share

  88. HENSLEY PJ, Bree KK, Campbell MT, Alhalabi O, et al
    Progression of Disease after Bacillus Calmette-Guerin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    J Urol. 2021;206:1258-1267.
    >> Share

  89. SCHUETTFORT VM, Pradere B, D'Andrea D, Grossmann NC, et al
    Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
    J Urol. 2021;206:1122-1131.
    >> Share

    October 2021
  90. CHAPPIDI MR, Yang H, Meng MV, Bivalacqua TJ, et al
    Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
    J Urol. 2021 Oct 25:101097JU0000000000002308. doi: 10.1097/JU.0000000000002308.
    >> Share

  91. BREE KK, Navai N
    Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply.
    J Urol. 2021 Oct 25:101097JU0000000000002307. doi: 10.1097/JU.0000000000002307.
    >> Share

  92. DE LA CALLE CM, Patel SH, Kates M
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002306. doi: 10.1097/JU.0000000000002306.
    >> Share

  93. KHANNA A, Miest T, Sharma V, Campbell R, et al
    Role of Lymphadenectomy During Radical Cystectomy for Non-muscle Invasive Bladder Cancer: Results From a Multi-Institutional Experience.
    J Urol. 2021 Oct 25:101097JU0000000000002266. doi: 10.1097/JU.0000000000002266.
    >> Share

  94. LOTAN Y, de Jong J, Liu VYT, Bismar TA, et al
    Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    J Urol. 2021 Oct 13:101097JU0000000000002261. doi: 10.1097/JU.0000000000002261.
    >> Share

  95. GHOREIFI A, Douglawi A, Djaladat H
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Letter.
    J Urol. 2021;206:1071.
    >> Share

  96. SHARMA V, Miest TS, Chamie K, Matin SF, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
    J Urol. 2021;206:1072.
    >> Share

  97. KHANNA A, Zganjar A, Lyon T, Shah P, et al
    A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy.
    J Urol. 2021;206:970-977.
    >> Share

    September 2021
  98. CARY C, Tong Y, Linsell S, Ghani K, et al
    Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2021 Sep 23:101097JU0000000000002233. doi: 10.1097/JU.0000000000002233.
    >> Share

  99. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who do Not Receive Guideline-Concordant Care at the Population Level.
    J Urol. 2021 Sep 22:101097JU0000000000002229. doi: 10.1097/JU.0000000000002229.
    >> Share

  100. MONTORSI F, Moschini M, Necchi A, Deho F, et al
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Letter.
    J Urol. 2021 Sep 14:101097JU0000000000002237. doi: 10.1097/JU.0000000000002237.
    >> Share

  101. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Response.
    J Urol. 2021 Sep 14:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    >> Share

  102. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply.
    J Urol. 2021 Sep 2:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    >> Share

  103. SHARMA V, Miest TS, Juvet TS, Toussi A, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
    J Urol. 2021;206:558-567.
    >> Share

  104. PETROS FG, Choi W, Qi Y, Moss T, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2021;206:548-557.
    >> Share

  105. KATIMS AB, Say R, Derweesh I, Uzzo R, et al
    Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
    J Urol. 2021;206:568-576.
    >> Share

    August 2021
  106. D'ANDREA D, Black PC, Zargar H, Dinney CP, et al
    Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2021 Aug 27:101097JU0000000000002190. doi: 10.1097/JU.0000000000002190.
    >> Share

  107. PATEL HD, Patel SH, Blanco-Martinez E, Kuzbel J, et al
    Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
    J Urol. 2021 Aug 27:101097JU0000000000002189. doi: 10.1097/JU.0000000000002189.
    >> Share

  108. CHEVLI KK, Shore ND, Trainer A, Smith AB, et al
    Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    J Urol. 2021 Aug 26:101097JU0000000000002186. doi: 10.1097/JU.0000000000002186.
    >> Share

  109. MERSEBURGER AS, Castellano D, Powles T, Loriot Y, et al
    Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    J Urol. 2021;206:240-251.
    >> Share

  110. PATEL SR, Lerner SP
    Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma.
    J Urol. 2021;206:191-193.
    >> Share

    July 2021
  111. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    >> Share

  112. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    >> Share

    June 2021
  113. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    >> Share

    May 2021
  114. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    >> Share

  115. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    >> Share

  116. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    >> Share

  117. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    >> Share

  118. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    >> Share

  119. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    >> Share

    April 2021
  120. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    >> Share

  121. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    >> Share

  122. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    >> Share

  123. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    >> Share

    March 2021
  124. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    >> Share

  125. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    >> Share


  126. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    >> Share


  127. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    >> Share

  128. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    >> Share

  129. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    >> Share

  130. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    >> Share

    February 2021
  131. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    >> Share

  132. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    >> Share

  133. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    >> Share

  134. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    >> Share

  135. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    >> Share

  136. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    >> Share

  137. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    >> Share

  138. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    >> Share

  139. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    >> Share

  140. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    >> Share

  141. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    >> Share

  142. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    >> Share

    January 2021
  143. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    >> Share

  144. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    >> Share

  145. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    >> Share

  146. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    >> Share

  147. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    >> Share

  148. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    >> Share

    December 2020
  149. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    >> Share

  150. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    >> Share

  151. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    >> Share

  152. CHANG SS
    Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?
    J Urol. 2020;204:1378.
    >> Share

  153. MORI K, Abufaraj M, Mostafaei H, Quhal F, et al
    A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    J Urol. 2020;204:1129-1140.
    >> Share

    November 2020
  154. DE JONG FC, Hoedemaeker RF, Kvikstad V, Mensink JTM, et al
    T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.
    J Urol. 2020 Nov 16:101097JU0000000000001422. doi: 10.1097/JU.0000000000001422.
    >> Share

  155. YIN G, Tang J, Wang L
    Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boeve, E. H. G. M. Oomens, N. J. van Casteren, M. Krispi
    J Urol. 2020;204:1062.
    >> Share

  156. HANNA PT, Peterson M, Albersheim J, Drawz P, et al
    Acute Kidney Injury following Enhanced Recovery after Surgery in Patients Undergoing Radical Cystectomy.
    J Urol. 2020;204:982-988.
    >> Share

  157. WANG DS
    Re: Epidural Anesthesia is Associated with Increased Complications in Cystectomy Patients: A NSQIP Analysis.
    J Urol. 2020;204:1072-1073.
    >> Share

    October 2020
  158. MYRIE AK, Matulewicz RS
    Perceptions of the Link Between Smoking and Bladder Cancer Among United States Adults.
    J Urol. 2020 Oct 14:101097JU0000000000001415. doi: 10.1097/JU.0000000000001415.
    >> Share

  159. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    >> Share

  160. ALMASSI N, Cha EK, Vertosick EA, Huang C, et al
    Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
    J Urol. 2020;204:677-684.
    >> Share

  161. CACCIAMANI GE, Ghodoussipour S, Mari A, Gill KS, et al
    Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    J Urol. 2020;204:649-660.
    >> Share

    September 2020
  162. LAVIANA AA, Stone BV, Avulova S
    Editorial Comment.
    J Urol. 2020;204:458-459.
    >> Share

  163. KRETSCHMER A
    Editorial Comment.
    J Urol. 2020;204:458.
    >> Share

  164. CHANG SS
    Editorial Comment.
    J Urol. 2020;204:449.
    >> Share

  165. CADEDDU JA
    Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    J Urol. 2020;204:598.
    >> Share

  166. DASON S, Cha EK, Falavolti C, Vertosick EA, et al
    Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations.
    J Urol. 2020;204:460-465.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016